Literature DB >> 9990411

Fusidic acid in dermatology.

J D Wilkinson1.   

Abstract

Fusidic acid is an antibiotic that belongs to a group of its own, the fusidanes. The molecule has a steroid-like structure but does not possess any steroid activity. The structure is thought to be responsible for the steroid-like high penetration, and for the fact that no cross-resistance or cross-allergy has been seen with other antibiotics in routine clinical use. The anti-microbial activity of fusidic acid is specifically aimed at the most common skin pathogens, including Staphylococcus aureus, towards which it is one of the most potent antibiotics. The place of fusidic acid in dermatology is in the treatment of mild to moderately severe skin and soft-tissue infections, e.g. impetigo, folicullitis, erythrasma, furunculosis, abscesses and infected traumatic wounds, whereas it is of less use in conditions such as hidradenitis suppurativa, chronic leg ulcers, burns and pressure sores. The topical combinations of fusidic acid with either betamethasone or hydrocortisone are extremely useful in the treatment of atopic dermatitis/eczema whenever staphylococcal/secondary infection is suspected, and in more persistent cases of eczema where staphylococcal superantigen may be playing an important exacerbating role.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9990411     DOI: 10.1046/j.1365-2133.1998.1390s3037.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

Review 1.  [Topical antibiotics in skin infections].

Authors:  D Thaçi; H Schöfer
Journal:  Hautarzt       Date:  2005-04       Impact factor: 0.751

2.  Atopic dermatitis.

Authors:  Thomas Bieber
Journal:  Ann Dermatol       Date:  2010-05-17       Impact factor: 1.444

Review 3.  Management of cutaneous erythrasma.

Authors:  Mack R Holdiness
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Epidemiology of European community-associated methicillin-resistant Staphylococcus aureus clonal complex 80 type IV strains isolated in Denmark from 1993 to 2004.

Authors:  A R Larsen; S Böcher; M Stegger; R Goering; L V Pallesen; R Skov
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

Review 5.  Role of bacterial pathogens in atopic dermatitis.

Authors:  Yu-Tsan Lin; Chen-Ti Wang; Bor-Luen Chiang
Journal:  Clin Rev Allergy Immunol       Date:  2007-12       Impact factor: 8.667

Review 6.  Bacterial skin infections in the elderly: diagnosis and treatment.

Authors:  Simone Laube; Anne M Farrell
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 7.  Fusidic acid resistance in Staphylococcus aureus.

Authors:  D Dobie; J Gray
Journal:  Arch Dis Child       Date:  2004-01       Impact factor: 3.791

8.  The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis.

Authors:  Mehdi Goudarzi; Bahareh Hajikhani; Sareh Kakavandi; Sana Amini; Samira Zamani; Alex van Belkum; Hossein Goudarzi; Masoud Dadashi
Journal:  Antimicrob Resist Infect Control       Date:  2021-05-01       Impact factor: 6.454

Review 9.  Impetigo - review.

Authors:  Luciana Baptista Pereira
Journal:  An Bras Dermatol       Date:  2014 Mar-Apr       Impact factor: 1.896

10.  Origin and evolution of European community-acquired methicillin-resistant Staphylococcus aureus.

Authors:  Marc Stegger; Thierry Wirth; Paal S Andersen; Robert L Skov; Anna De Grassi; Patricia Martins Simões; Anne Tristan; Andreas Petersen; Maliha Aziz; Kristoffer Kiil; Ivana Cirković; Edet E Udo; Rosa del Campo; Jaana Vuopio-Varkila; Norazah Ahmad; Sima Tokajian; Georg Peters; Frieder Schaumburg; Barbro Olsson-Liljequist; Michael Givskov; Elizabeth E Driebe; Henrik E Vigh; Adebayo Shittu; Nadjia Ramdani-Bougessa; Jean-Philippe Rasigade; Lance B Price; Francois Vandenesch; Anders R Larsen; Frederic Laurent
Journal:  MBio       Date:  2014-08-26       Impact factor: 7.867

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.